NCT04996095Fut, nem toboroz
The Registry Study of Genetic Alterations of Esophageal Cancer in Taiwan
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. ápr. 17.
Rövid összefoglaló (regiszter, angolul)
Protocol Objectives Establish a platform for sharing integrated database of genetic background, clinical information, and therapeutic outcomes in locally advanced and recurrent/metastatic ESCC. To enroll a total of 400 ESCC patients with different ages and stages according to the eligibility criteria defined in section 5 and section 6.To perform NGS analysis of ESCC tumor tissues, and correlated with the clinical characteristics and treatment outcomes of ESCC patients.To compare the difference of the genetic and molecular profiles among different age groups of ESCC patients.To reveal the evolution changes of genetic and molecular profiles of ESCC by comparing the difference of genetic and molecular alterations between primary and recurrent ESCC and between locally advanced and metastatic ESCC. 。 Study Method, Procedures, and Implementation Status Sample size: 400 patients with ESCC who fit inclusion criteria and exclusion criteria listed in session 6 of the study proposal. 1. To meet the study object of investigating "the difference of the genetic and molecular profiles among different age groups", a minimum of 75 young ESCC patients (with age of ESCC diagnosis at 20-45 years old) and a minimum of 75 elderly ESCC patients (with age of ESCC diagnosis at ≥ 75 years old) will be recruited. 2. To meet the study object of investigating "the evolution changes of genetic and molecular profiles of ESCC", an approximate of 100 recurrent or metastatic ESCC tumors will be included. Centralized Planning Unit and Assisting Unit: Taiwan Cooperative Oncology Group (TCOG), National Health Research Institutes
- Állapot (regiszter)
- Fut, nem toboroz
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 400 (tényleges)
- Első benyújtás
- 2021. júl. 30.
- Kezdés
- 2021. okt. 1.
- Elsődleges befejezés
- 2029. dec. 31.
- Fő szponzor
- National Health Research Institutes, Taiwan
- Betegségek
- Gyomor- és nyelőcsőrák
- NCT-szám
- NCT04996095
Mit vállalsz
- Vizsgálat típusa: Megfigyeléses
- Bevont résztvevők: 400
- 2021. okt. 1. és az elsődleges befejezés (2029. dec. 31.) között
- 2 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- 1. Inability to cooperate by providing a complete medical history. 2. No available tumor tissues for genetic testing. 3. Undesirable compliance. 4. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.
Kiket keres a vizsgálat
- 1. Cohort 1 (young ESCC): aged 20 ~ 45 years old; Cohort 2 (reference-age ESCC): aged 46 ~ 74 years old); and Cohort 3 (elderly ESCC): aged 75 years or older.
- Pathological reported as squamous cell carcinoma of the esophagus 3. Staged as clinical or pathological stage II to IVA in loco-regional ESCC group (per AJCC Cancer Staging System 8th edition); stage IVB in the metastatic group; or recurrent status (defined as disease recurrence occurring more than 6 months after curative chemoradiotherapy or surgery) in the recurrent group.
- Willingness to provide archival or newly obtained tumor tissues for current study proposal.
- Life expectancy more than 3 months. 6. Patients fully understand the protocol with the willingness to have regular follow-up.
- 6.2. Exclusion Criteria
- Inability to cooperate by providing a complete medical history.
- No available tumor tissues for genetic testing.
- Undesirable compliance.
- Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.
Életkor a regiszterben: 20 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (2)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Shang-Hung Chen | Tainan | Tajvan | Ismeretlen állapot |
| Taiwan Cooperative Oncology Group, National Health Research Institutes | Taipei | Tajvan | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.